Patent details

Basic Information

Publication number:

EP2889310

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP151557121

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

Antibody formulations

French Title of Invention:

Formulations d'anticorps

German Title of Invention:

Antikörper-Formulierungen

SPC Number:

Dates

Filing date:

03/07/2008

Grant date:

20/12/2017

EP Publication Date:

01/07/2015

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

20/12/2017

EP B1 Publication Date:

20/12/2017

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

03/07/2028

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

13/12/2017

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:

Lashmar, Ulla Tove

Address:

United Kingdom (GB)

2

Name:

Ketkar, Amol Sharad

Address:

United States (US)

3

Name:

Brisbane, Charlene E

Address:

United States (US)

Priority

Priority Number:

948220 P

Priority Date:

06/07/2007

Priority Country:

United States (US)

Classification

IPC classification:

A61K 9/00; A61K 39/395; C07K 16/00; C07K 16/28;

Publication

European Patent Bulletin

Issue number:

201751

Publication date:

20/12/2017

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

31/07/2026

Annual Fee Number:

19

Annual Fee Amount:

281 Euro

Expected Payer:

Last Annual Fee Payment Date:

25/06/2025

Last Annual Fee Paid Number:

18

Last Annual Fee Paid Amount:

262 Euro

Payer:

CPA GLOBAL THE IP PLATFORM

Filing date	Document type	Number of pages